Why Farbe Firma is the Top Manufacturer of Ketorolac Tromethamine Injection
- Maulik Sudani
- 17h
- 7 min read
Last Updated: May 28, 2026
TL;DR: Ketorolac Tromethamine Injection — a sterile parenteral solution of the pyrrolizine-carboxylic-acid non-steroidal anti-inflammatory drug (NSAID) ketorolac tromethamine, supplied most commonly as 30 mg/mL in 1 mL ampoules and as 60 mg/2 mL ampoules — is the high-potency, opioid-sparing analgesic of choice for short-term management of moderate to severe acute pain in the immediate post-operative period, after orthopaedic and gynaecological surgery, and in acute musculoskeletal and renal-colic pain. Within 30 minutes of intramuscular or intravenous administration it produces opioid-equivalent analgesia for many indications by reversibly inhibiting cyclooxygenase-1 and cyclooxygenase-2 and suppressing peripheral prostaglandin synthesis. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Ketorolac Tromethamine Injection at our Gujarat, India facility and supplies it to hospital tenders, post-operative analgesia programmes, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Pyrrolizine-carboxylic-acid non-steroidal anti-inflammatory drug (NSAID) — Ketorolac Tromethamine Injection is one of the most potent parenteral NSAIDs in clinical use, indicated for the short-term (up to five days) management of moderately severe acute pain that would otherwise require an opioid. As a non-narcotic, opioid-sparing analgesic it allows surgical, orthopaedic and emergency teams to reduce opioid exposure without compromising pain control.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified clear-glass ampoule and vial filling lines, dedicated handling for a water-soluble, pH-sensitive NSAID salt, validated terminal-sterilisation cycles and full container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations across regulated and emerging markets — including ministry-of-health hospital and post-operative-pain tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready ampoule packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Ketorolac Tromethamine Injection Demands a Premium Manufacturer
Ketorolac Tromethamine Injection is the analgesic that anaesthesia, surgical and emergency teams reach for when they want opioid-equivalent pain relief without an opioid. It is given as a 30 mg or 60 mg intramuscular dose at the end of a surgical case to set up the first six hours of post-operative analgesia; it is given intravenously in 15–30 mg doses for acute renal colic and acute musculoskeletal pain in the emergency department; and it is used as part of multimodal pain protocols on orthopaedic and gynaecological wards where the goal is to keep patients comfortable while reducing total opioid exposure. The product is given to patients in acute pain who expect rapid relief, and it is given under regulatory protocols that limit total dose and total duration of therapy — both of which depend absolutely on accurate strength and accurate labelling.
That clinical reality places real demands on the manufacturer. Ketorolac tromethamine is the highly water-soluble tromethamine salt of ketorolac, formulated as a clear, sterile aqueous solution buffered close to physiological pH and protected from light through its shelf life. The drug is sensitive to oxidation and to pH excursions, and the parenteral solution must be packed in containers and cartons that prevent both light damage and air ingress during distribution. Assay precision is non-negotiable because the difference between a 15 mg, 30 mg and 60 mg dose has real clinical and regulatory consequences, particularly when treatment is limited to five days and total cumulative exposure is being tracked. Choosing a Ketorolac Tromethamine Injection manufacturer that treats potency control, pH and oxidative stability, and unambiguous strength differentiation as core engineering disciplines is what protects post-operative analgesia at the bedside.
What Sets a World-Class Ketorolac Tromethamine Injection Manufacturer Apart
A world-class manufacturer of Ketorolac Tromethamine Injection invests in three areas that weaker suppliers underfund: precision assay and stability control of a high-potency analgesic, unambiguous strength differentiation between 15 mg, 30 mg and 60 mg presentations, and tender-ready dossier support for a product that is almost always procured through hospital and ministry-of-health channels. It starts with the active pharmaceutical ingredient — pharmacopoeial-grade ketorolac tromethamine sourced from qualified, audited API manufacturers, with full impurity profiling, related-substances control and certificates of analysis cross-checked by the receiving laboratory before any material enters production.
Formulation, filling and packaging then have to protect the molecule end to end. The solution is built at a controlled pH (around 6.9 to 7.9) using ethanol and sodium chloride as stabilising excipients, and is filled under ISO Class 5 air into clear-glass ampoules and vials with light-protective secondary packaging. In-process assay confirms label strength, container-closure integrity is verified on every batch, and stability is tracked under ICH Q1A long-term and accelerated conditions as well as ICH Q1B photostability protocols. Critically, the artwork programme keeps the 15 mg, 30 mg and 60 mg presentations visually distinct — different ampoule and carton colours, large strength callouts — because these strengths are routinely stocked together in operating rooms, recovery areas and emergency departments where selection errors must not occur.
Quality Systems Behind Every Ketorolac Tromethamine Injection
Every Farbe Firma Ketorolac Tromethamine Injection batch is released only after a full stack of quality checks: HPLC assay against USP, BP, IP or EP reference standards, related-substances and degradation-product profiling, pH, osmolarity, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, container-closure integrity, and fill-volume verification for both the 1 mL and 2 mL ampoule formats. Certificates of analysis are issued with full traceability back to API lot, primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated terminal sterilisation cycles with load mapping for each container format, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions — Zone IVb included — and the product is challenged against ICH Q1B photostability requirements so we can assure customers that the Ketorolac Tromethamine Injection they buy today will still meet specification when it reaches the recovery room or emergency department months later in any climate.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Ketorolac Tromethamine Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across pain-management, anaesthesia, anti-infective, obstetric, neonatal and supportive-care categories. For Ketorolac Tromethamine Injection specifically, we supply 15 mg, 30 mg and 60 mg strengths in 1 mL and 2 mL clear-glass ampoules and vials under WHO-GMP conditions, with country-specific strengths, container formats and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier ready to hand for registration in the buyer's target market.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination. When a buyer needs Ketorolac Tromethamine Injection at tender scale — and post-operative and emergency-pain procurements are almost always high-volume, multi-strength and label-sensitive — our regulatory, manufacturing and logistics teams move as one: dossier, artwork, production slot and shipment plan delivered as a single coordinated package, with a single accountable point of contact.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, pH stabilisation, oxidative-stability control, photostability, sterilisation, container-closure and stability choices in real detail. For a drug given to patients in acute post-operative and emergency pain, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Ketorolac Tromethamine Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Ketorolac Tromethamine Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule and vial filling lines, qualified water-for-injection systems, validated terminal sterilisation cycles and continuous environmental monitoring. WHO-GMP, USP, BP, IP and EP compliance documentation is available on request.
Which strengths and pack sizes of Ketorolac Tromethamine Injection do you supply?
Our standard presentations are 30 mg/mL ketorolac tromethamine solution in 1 mL clear-glass ampoules and vials (30 mg) and 60 mg per 2 mL ampoules. A 15 mg/mL presentation is also available under contract. Custom fill volumes, multi-dose vial presentations and country-specific pack configurations are available.
Can Farbe Firma support country-specific registrations for Ketorolac Tromethamine Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. Our regulatory team has supported registrations across 30+ countries in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma assure the potency and stability of Ketorolac Tromethamine Injection?
We control pH within a validated near-physiological specification, run HPLC assay and related-substances testing on every batch, package in clear-glass ampoules and vials with light-protective secondary cartons, and qualify each batch against ICH Q1A long-term and accelerated stability protocols plus ICH Q1B photostability. Endotoxin, sterility and container-closure integrity are confirmed on every batch.
What is the minimum order quantity for Ketorolac Tromethamine Injection contract manufacturing?
MOQs vary by strength, container format, label complexity and dossier requirements. For the 15 mg, 30 mg and 60 mg ampoule and vial presentations we accommodate hospital-scale and full-tender-scale orders. Contact director@farbefirma.org for a specific quotation against your specification.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments